Buy Afinitor

Afinitor

What is Afinitor?

Afinitor contains everolimus as its active component. Everolimus is an oral mTOR (mechanistic target of rapamycin) inhibitor used as part of oncology support therapy. The medication is supplied as a pill in two strengths-5 mg and 10 mg. In Hong Kong, Afinium is a prescription-only (Rx) drug regulated by the Department of Health under the Medicines and Poisons Ordinance.

How Afinitor Works in the Body

Everolimus belongs to the rapamycin-derived class of targeted therapies. It binds to the intracellular protein FKBP-12, forming a complex that blocks the mTORC1 signaling pathway. By inhibiting mTORC1, everolimus reduces cell proliferation, angiogenesis, and protein synthesis-processes that many cancer cells rely on for growth and survival. The drug’s effect begins within hours of the first dose, reaches steady-state concentrations after about a week of daily dosing, and its pharmacologic activity persists for the dosing interval.

Conditions Treated by Afinitor

Afinitor is approved by major regulatory agencies for several oncology indications, including:

• Advanced renal cell carcinoma (RCC) after prior vascular endothelial growth factor (VEGF)-targeted therapy
• Hormone-receptor-positive, HER2-negative advanced breast cancer in combination with exemestane following endocrine therapy failure
• Unresectable or metastatic well-differentiated neuroendocrine tumors of pancreatic or gastrointestinal origin
• Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex

These approvals are reflected in the product label used in Hong Kong and align with FDA and EMA indications.

Off-Label and Investigational Applications

Evidence-Based Off-Label Uses

• Advanced pancreatic cancer: Small phase II trials have explored everolimus combined with chemotherapy, showing modest activity. Use remains off-label and should be considered only within a clinical trial or under specialist supervision.
• Certain solid tumors (e.g., melanoma, sarcoma): Early-phase studies indicate potential benefit, but definitive efficacy data are lacking.

All off-label applications require individualized risk assessment and close monitoring by an oncology specialist.

Who Should (Not) Use Afinitor?

Ideal Patient Profile

• Adults with one of the FDA/EMA-approved cancer types listed above
• Patients with adequate organ function (e.g., liver enzymes ≤ 2 × ULN, creatinine clearance ≥ 30 mL/min)
• Individuals able to adhere to daily oral dosing and scheduled monitoring

Absolute Contraindications

• Known hypersensitivity to everolimus or any excipients in the pill
• Pregnancy (everolimus is teratogenic) or lactation
• Concurrent use of strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that would substantially lower drug exposure

Relative Contraindications

• Moderate hepatic impairment (Child-Pugh B) - dose reduction may be needed
• Severe renal impairment (creatinine clearance < 30 mL/min) - careful monitoring advised
• Active uncontrolled infection (e.g., tuberculosis, opportunistic fungal infection)

Special Populations

• Pregnancy/Lactation: Everolimus is classified as Category X; avoid use. Effective contraception is required during treatment and for at least 2 weeks after the last dose.
• Elderly: No specific dose adjustment, but increased susceptibility to infections and hematologic toxicity warrants closer observation.
• Pediatric: Afinitor is not approved for routine pediatric oncology use; dosing in children is limited to specific trials (e.g., SEGA).

Safety Profile: Side Effects and Interactions

Common Side Effects

• Stomatitis (mouth sores): frequently reported; oral rinses with saline or baking-soda may alleviate discomfort.
• Rash or acne-like lesions: usually mild and self-limiting.
• Diarrhea: maintain hydration; antidiarrheal agents can be used under physician guidance.
• Fatigue: adjust activity levels and ensure adequate rest.
• Hyperglycemia: monitor blood glucose, especially in patients with diabetes.

Serious Adverse Events

• Pneumonitis (non-infectious lung inflammation): presents with cough or dyspnea; requires prompt evaluation and possible drug interruption.
• Severe infections (bacterial, viral, fungal): vigilance for fever, chills, or localized signs of infection is essential.
• Hematologic toxicity (anemia, neutropenia, thrombocytopenia): routine blood counts are mandatory.
• Renal failure: monitor serum creatinine; dose reductions may be needed.

Drug Interactions

• Major Interactions: Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase everolimus concentrations → risk of toxicity. Dose reduction is recommended.
• Moderate Interactions: CYP3A4 inducers (e.g., St. John’s wort, phenytoin) may lower drug levels → therapeutic failure risk. Consider alternative agents or dose increase under specialist advice.
• Immunosuppressants: Co-administration with tacrolimus or cyclosporine can raise everolimus levels; monitor trough concentrations closely.

Food and Lifestyle Interactions

• Meal timing: Take Afinitor on an empty stomach-at least 1 hour before or 2 hours after food-to improve absorption.
• Alcohol: Excessive intake may worsen liver toxicity; moderate consumption is advisable.
• Driving: Everolimus can cause fatigue or dizziness; patients should assess their ability to operate machinery safely.

How to Take Afinitor

• Standard dosing: The typical starting dose for most approved indications is 10 mg taken orally once daily with a glass of water.
• Dose reductions: If intolerable toxicity occurs, the dose may be reduced to 5 mg once daily. Further reductions below 5 mg are uncommon and should be guided by a specialist.
• Administration: Swallow the pill whole; do not crush, split, or chew.
• Missed dose: If a dose is forgotten, take it as soon as remembered unless it is within 12 hours of the next scheduled dose-do not double-dose.
• Overdose: Symptoms may include severe nausea, vomiting, diarrhea, and respiratory distress. Seek emergency medical attention; supportive care is the mainstay. No specific antidote is available.
• Discontinuation: Abrupt cessation is permissible; however, for some indications (e.g., transplant “off-label” use) a taper may be recommended. Always follow the oncologist’s guidance.

Monitoring and Follow-Up

• Baseline labs: Complete blood count, liver function tests, serum creatinine, fasting glucose, lipid panel.
• Ongoing labs: CBC, renal and hepatic panels every 2-4 weeks for the first 3 months, then every 8-12 weeks once stable.
• Imaging: Disease-specific scans (CT, MRI, or PET) at intervals defined by the treating oncologist to assess therapeutic response.
• Clinical assessment: Prompt reporting of new cough, fever, skin changes, or gastrointestinal symptoms.

Storage and Handling

• Store Afinitor tablets at room temperature (20-25 °C), protected from light and moisture.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiration date printed on the label.
• Dispose of unused tablets according to local pharmaceutical waste guidelines (e.g., return to a pharmacy or follow HK Department of Health disposal instructions).

Medication-Specific Glossary

mTOR (mechanistic Target of Rapamycin)

A cellular kinase that regulates growth, proliferation, and survival; inhibition slows cancer cell expansion.

CYP3A4

A liver enzyme that metabolizes many drugs; strong inhibitors raise everolimus levels, while inducers lower them.

Stomatitis

Inflammation of the mouth lining, often presenting as painful ulcers; a common side effect of mTOR inhibitors.

Pneumonitis

Non-infectious inflammation of lung tissue that can cause cough and shortness of breath; may require treatment interruption.

Therapeutic Window

The dosage range in which a drug is effective without causing unacceptable toxicity; everolimus’s window is narrow, emphasizing the need for monitoring.

Medical Disclaimer

This article provides educational information about Afinitor and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.